表紙
市場調查報告書

中國的獨立型臨床檢驗產業報告 (2019∼2025年)

China Independent Clinical Laboratory Industry Report, 2019-2025

出版商 ResearchInChina 商品編碼 248741
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
中國的獨立型臨床檢驗產業報告 (2019∼2025年) China Independent Clinical Laboratory Industry Report, 2019-2025
出版日期: 2019年04月28日內容資訊: 英文 140 Pages
簡介

中國的獨立臨床實驗室產業仍處於起步階段。在2018年普及率僅為5%左右,遠低於歐洲,美國和日本的水準(40%或更高)。但市場成長率相當高,2010∼2018年的年複合成長率 (CAGR) 達40.9%,2018年的市場規模達到186億人民幣 (與前一年同期比較增加了37.8%) 。企業間競爭正在劇烈化,今後預料不具成本優勢的小規模企業將會退出。

本報告提供中國的獨立型臨床檢驗產業調查分析,彙整產業政策,市場環境,現狀,競爭情形,趨勢與預測,上游/下游產業的發展等資料,也包含主要企業簡介,為您概述為以下內容。

第1章 獨立型臨床檢驗室概要

  • 定義
  • 相關產業結構

第2章 中國的獨立型臨床檢驗產業概要

  • 政策環境
    • 使用政策
    • 產業政策
  • 國際環境
    • 現狀
    • 企業比較分析
  • 現狀
  • 市場規模
  • 競爭環境
  • 發展趨勢
    • 產業規模的持續性擴大
    • 階層性的醫療制度,促進產業的迅速發展
    • 公立醫院的檢驗業務外包化 (成本控制)
    • 高階檢驗產品的收益額佔有率的增加
    • 私立醫院的迅速發展
    • 獨立臨床實驗室機構將在快速技術升級中成為技術領導者
    • 人口高齡化
    • 互聯網將刺激獨立臨床實驗室產業的商業模式升級
    • 由於競爭激烈,小規模企業的退出

第3章 中國的獨立型臨床檢驗產業的上游/下游工程

  • 上游工程部門
    • 現狀
    • 市場規模
    • 競爭環境
    • 發展趨勢
  • 下游工程部門
    • 品質
    • 醫療服務
    • 市場收益額
    • 醫療費

第4章 主要企業

  • KingMed Diagnostics
    • 簡介
    • 經營情形
    • 收益結構
    • 毛利率
    • 研究開發 (R&D)·投資
    • 主要客戶
    • 獨立型臨床檢驗事業
    • 發展策略
  • DIAN Diagnostics
  • Shanghai Labway Clinical Laboratory
  • DAAN Gene
  • ADICON Clinical Laboratories
  • NYMPHAVN Biotechnology
  • SurExam Biotechnology
  • MedicalSystem Biotechnology
  • Beijing Lawke Health Laboratory
  • Beijing Lepu Gene Technology
  • Shanghai Biotecan Pharmaceuticals
  • Jiangsu Superbio Life Science
  • Amoy Diagnostics
  • Guangdong Hybribio Biotech
  • 其他的企業
    • Kindstar Global
    • CapitalBio Corporation
    • Beijing Adinovo Gene Technology Co., Ltd.
    • Deyi Diagnostics
    • IPE Center for Clinical Laboratory
    • Centre Testing International Group Co., Ltd. (CTI)
    • SinoPath Diagnosis

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main reason is that the laboratory and pathology departments of public hospitals occupy the leading position in the industry in China.

In China, large independent clinical laboratories can provide more than 2,000 test items, while first-class AAA hospitals can only offer over 300-500 test items. With the acceleration of population aging, higher incidence of various chronic diseases and favorable policies, the penetration rate and scale of China's independent clinical laboratory industry will increase year by year.

China's independent clinical laboratory market size presented the CAGR of 40.9% during 2010-2018, and approximated RMB18.6 billion in 2018, a year-on-year increase of 37.8%. By 2025, it is expected to reach RMB96.7 billion with the growth rate of above 20%.

As of September 2018, there had been 1,271 independent clinical laboratories in China, indicating gradually intensified competition in the industry. At present, major players in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, MedicalSystem Biotechnology and so forth. Particularly, KingMed Diagnostics is the industry's leader with a 22.8% market share in 2018.

As the competition intensifies, the market share of the giant KingMed Diagnostics has reduced from 32.9% in 2014 to 22.8% in 2018. In the future, small ICL companies without competitive advantages are likely to be phased out and the industry will be more concentrated.

China Independent Clinical Laboratory Industry Report, 2019-2025 highlights the following:

Overview of China's independent clinical laboratory industry, covering development environment, status quo, market size, competitive landscape and development trend;

Upstream and downstream sectors of China's independent clinical laboratory industry;

Operation, gross margin, R&D investment, independent clinical laboratory business and development strategy of 21 companies in China.

Table of Contents

1. Overview of Independent Clinical Laboratory

  • 1.1 Definition
  • 1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry

  • 2.1 Policy Environment
    • 2.1.1 Access Policy
    • 2.1.2 Industry Policy
  • 2.2 International Environment
    • 2.2.1 Status Quo
    • 2.2.2 Benchmarking Enterprises
  • 2.3 Status Quo
  • 2.4 Market size
  • 2.5 Competitive Landscape
  • 2.6 Development Trends
    • 2.6.1 Industry Scale Expands Constantly
    • 2.6.2 Hierarchical Medical System Will Boost the Rapid Development of the Industry
    • 2.6.3 The Laboratory Outsourcing Proportion of Public Hospitals Will Rise due to Cost Control
    • 2.6.4 High-end Test Items Will Make More Revenue Contribution
    • 2.6.5 The Rapid Development of Private Hospitals Will Stimulate the Demand in the Independent Clinical Laboratory Market
    • 2.6.6 Independent Clinical Laboratory Institutions Will Become Technical Leaders amid Quick Technological Upgrades
    • 2.6.7 The Aging Population Balloons and the Demand for Medical Laboratory Will Soar
    • 2.6.8 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry
    • 2.6.9 Intensified industry competition Forced Small Capacity to Withdraw

3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry

  • 3.1 Upstream Sector
    • 3.1.1 Status Quo
    • 3.1.2 Market Size
    • 3.1.3 Competitive Landscape
    • 3.1.4 Development Trend
  • 3.2 Downstream Sector
    • 3.2.1 Quantity
    • 3.2.2 Medical Services
    • 3.2.3 Revenue
    • 3.2.4 Health Costs

4. Key Players

  • 4.1 KingMed Diagnostics
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D and Investment
    • 4.1.6 Major Customers
    • 4.1.7 Independent Clinical Laboratory Business
    • 4.1.8 Development Strategy
  • 4.2 DIAN Diagnostics
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D and Investment
    • 4.2.6 Independent Clinical Laboratory Business
    • 4.2.7 Development Strategy
  • 4.3 Shanghai Labway Clinical Laboratory
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D and Investment
    • 4.3.6 Independent Clinical Laboratory Business
  • 4.4 DAAN Gene
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 R&D and Investment
    • 4.4.5 Major Customers
    • 4.4.6 Independent Clinical Laboratory Business
    • 4.4.7 Development Strategy
  • 4.5 ADICON Clinical Laboratories
    • 4.5.1 Profile
    • 4.5.2 Independent Clinical Laboratory Business
    • 4.5.3 Developments
  • 4.6 NYMPHAVN Biotechnology
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 R&D and Investment
    • 4.6.6 Independent Clinical Laboratory Business
    • 4.6.7 Development Strategy
  • 4.7 SurExam Biotechnology
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 Independent Clinical Laboratory Business
  • 4.8 MedicalSystem Biotechnology
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 R&D and Investment
    • 4.8.6 Independent Clinical Laboratory Business
    • 4.8.7 Development Strategy
  • 4.9 Beijing Lawke Health Laboratory
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Revenue Structure
    • 4.9.4 Gross Margin
    • 4.9.5 R&D and Investment
  • 4.10 Beijing Lepu Gene Technology
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 R&D and Investment
    • 4.10.6 Major Customers
  • 4.11 Shanghai Biotecan Pharmaceuticals
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Revenue Structure
    • 4.11.4 Gross Margin
    • 4.11.5 Independent Clinical Laboratory Business
  • 4.12 Jiangsu Superbio Life Science
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Revenue Structure
    • 4.12.4 Gross Margin
    • 4.12.5 Financing
  • 4.13 Amoy Diagnostics
    • 4.13.1 Profile
    • 4.13.2 Operation
    • 4.13.3 Revenue Structure
    • 4.13.4 Gross Margin
    • 4.13.5 Independent Clinical Laboratory Business
    • 4.13.6 Development Strategy
  • 4.14 Guangdong Hybribio Biotech
    • 4.14.1 Profile
    • 4.14.2 Operation
    • 4.14.3 Revenue Structure
    • 4.14.4 Gross Margin
    • 4.14.5 R&D
    • 4.14.6 Independent Clinical Laboratory Business
    • 4.14.7 Development Strategy
  • 4.15 Other Enterprises
    • 4.15.1 Kindstar Global
    • 4.15.2 CapitalBio Corporation
    • 4.15.3 Beijing Adinovo Gene Technology Co., Ltd.
    • 4.15.4 Deyi Diagnostics
    • 4.15.5 IPE Center for Clinical Laboratory
    • 4.15.6 Centre Testing International Group Co., Ltd. (CTI)
    • 4.15.7 SinoPath Diagnosis

Selected Charts

Independent Clinical Laboratory Industry Chain

Comparison of Independent Clinical Laboratory Undertakers between China and USA

Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2018

Development History of U.S. Independent Clinical Laboratory Industry

U.S. Independent Clinical Laboratory Market Share by Test Item

U.S. Clinical Laboratory Market Share by Demand Side

Comparison of Independent Clinical Laboratory Market Penetration among Europe, Americas and Japan, 2018

Revenue and Net Income of Quest Diagnostics, 2009-2018

Revenue of Quest Diagnostics by Business, 2014-2018

Major M&As of Quest Diagnostics, 2006-2018

Revenue and Operating Income of LabCorp, 2010-2018

Revenue Breakdown of LabCorp by Division, 2013-2018

Revenue Structure of LabCorp by Division, 2013-2018

Major M&As of LabCorp, 2007-2017

Comparison of Independent Clinical Laboratory Market Penetration between China, and Europe, Americas and Japan, 2018

Comparison of Number of Diagnostic Items among Various Medical Institutions

Independent Clinical Laboratory Market Size in China, 2010-2018

Number of Independent Clinical Laboratories in China, 2007-2018

Independent Clinical Laboratory Revenue of Main Independent Clinical Laboratory Enterprises in China, 2014-2018

Marker Share of Independent Clinical Laboratory Enterprises in China, 2018

Independent Clinical Laboratory Market Size and YoY Growth in China, 2018-2025E

Policies Concerning Public Hospital Reform in China, 2015-2019

Number of Private Hospitals and YoY Growth in China, 2009-2018

Clinic Visits of Private Hospitals in China, 2012-2018

Population Aged over 60 in China, 2009-2018

Market Share of KingMed Diagnostics, 2014-2018

Classification of In Vitro Diagnosis

Development History of In Vitro Diagnostic Industry in China

In Vitro Diagnosis Market Size in China, 2009-2018

In Vitro Diagnosis Market Size in China, 2018-2025E

In Vitro Diagnosis Market Structure in China, 2018

Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Enterprises

Competition Pattern of Diagnostic Reagent Industry in China

IVD Revenue of Major Diagnostic Reagent Enterprises in China, 2014-2018

IVD Market Share of Major Diagnostic Reagent Enterprises in China, 2014-2018

Population Aged over 60 in China, 2009-2018

Policies Concerning In Vitro Diagnosis in China

Comparison of Prospects between In Vitro Diagnosis Segments in China

Number of Medical and Health Institutions in China, 2015-2018

Number of Hospitals in China, 2009-2018

Number of Hospitals in China by Economic Type, 2009-2018

Clinic Visits of Medical Institutions in China, 2015-2018

Clinic Visits of Hospitals in China, 2009-2018

Clinic Visits of Hospitals in China by Economic Type, 2012-2018

Total Revenue of Medical and Health Institutions in China, 2010-2018

Total Revenue of Medical and Health Institutions in China, 2018-2025E

Total Revenue of Hospitals in China, 2009-2018

Public Hospitals' Inspection Revenue and % of Total Inspection Revenue in China, 2010-2018

Total Health Expenditure in China, 2010-2018

Revenue and Net Income of KingMed Diagnostics, 2014-2018

Revenue Breakdown of KingMed Diagnostics by Product, 2014-2018

Revenue Breakdown of KingMed Diagnostics by Region, 2014-2018

Gross Margin of KingMed Diagnostics by Product, 2014-2018

KingMed Diagnostics' R&D Costs and % of Total Revenue, 2014-2018

KingMed Diagnostics' Revenue from Top5 Clients and % of Total Revenue, 2014-2018

Independent Clinical Laboratory Subsidiaries of KingMed Diagnostics

Operating Results of Main Companies KingMed Diagnostics Controls or Has a Stake in, 2017-2018 (Unit: RMB mln)

Output, Capacity and Capacity Utilization of KingMed Diagnostics, 2014-2016

Unit Prices of Main Services of KingMed Diagnostics, 2014-2016

Revenue and Net Income of DIAN Diagnostics, 2013-2018

Revenue Breakdown of DIAN Diagnostics by Product, 2013-2018

Revenue Breakdown of DIAN Diagnostics by Region, 2013-2018

Gross Margin of DIAN Diagnostics by Business, 2013-2018

DIAN Diagnostics' R&D Costs and % of Total Revenue, 2013-2018

DIAN Diagnostics' Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2018

Independent Clinical Laboratory Subsidiaries of DIAN Diagnostics

Regional Layout of Shanghai Labway Clinical Laboratory

Revenue and Net Income of Shanghai Labway Clinical Laboratory, 2013-2017

Operating Revenue Breakdown of Shanghai Labway Clinical Laboratory by Business, 2013-2017

Gross Margin of Shanghai Labway Clinical Laboratory by Business, 2013-2016

Shanghai Labway Clinical Laboratory's R&D Costs and % of Total Revenue, 2013-2017

Independent Clinical Laboratory Subsidiaries of Shanghai Labway Clinical Laboratory

Main Diagnostic Items of Shanghai Labway Clinical Laboratory

Shanghai Labway Clinical Laboratory's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2017

Revenue and Net Income of DAAN Gene, 2013-2018

Revenue Breakdown of DAAN Gene by Product, 2013-2018

Revenue Breakdown of DAAN Gene by Region, 2013-2018

DAAN Gene's R&D Costs and % of Total Revenue, 2013-2018

DAAN Gene's Revenue from Top 5 Clients and % in Total Revenue, 2015-2018

DAAN Gene's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2018

Independent Clinical Laboratory Subsidiaries of DAAN Gene

Development Course of ADICON Clinical Laboratories

Revenue and Net Income of Nymphavn Biotechnology, 2013-2018

Revenue Breakdown of Nymphavn Biotechnology by Business, 2014-2018

Gross Margin of Nymphavn Biotechnology, 2013-2018

Nymphavn Biotechnology's R&D Costs and % of Total Revenue, 2013-2018

Nymphavn Biotechnology's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2018

Subsidiaries and Main Businesses of Surexam Biotechnology

Revenue and Net Income of SurExam Biotechnology, 2013-2018

Operating Revenue Breakdown of SurExam Biotechnology by Business, 2013-2018

Gross Margin of SurExam Biotechnology, 2013-2018

SurExam Biotechnology's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2017

Revenue and Net Income of Medicalsystem Biotechnology, 2013-2018

Revenue Breakdown of Medicalsystem Biotechnology by Business, 2013-2018

Gross Margin of Medicalsystem Biotechnology by Business, 2013-2018

Medicalsystem Biotechnology's R&D Costs and % of Total Revenue, 2013-2018

Investment Progress of Fundraising Projects of Medicalsystem Biotechnology by the end of 2018

Medicalsystem Biotechnology's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2013-2018

Financial Data of Main Independent Clinical Laboratory Subsidiaries of Medicalsystem Biotechnology, 2016-2018

Newly-established Independent Clinical Laboratory Subsidiaries of Medicalsystem Biotechnology, 2016-2018

Revenue and Net Income of Beijing Lawke Health Laboratory, 2013-2017

Revenue Breakdown of Beijing Lawke Health Laboratory by Region, 2014-2017

Gross Margin of Beijing Lawke Health Laboratory, 2013-2017

Beijing Lawke Health Laboratory's R&D Costs and % of Total Revenue, 2013-2017

Revenue and Net Income of Beijing Lepu Gene Technology, 2013-2018

Revenue Breakdown of Beijing Lepu Gene Technology by Business, 2014-2018

Gross Margin of Beijing Lepu Gene Technology, 2013-2018

Beijing Lepu Gene Technology's R&D Costs and % of Total Revenue, 2014-2018

Beijing Lepu Gene Technology's Revenue from Top 5 Clients and % in Total Revenue, 2015-2018

Revenue and Net Income of Shanghai Biotecan Pharmaceuticals, 2013-2017

Revenue Breakdown of Shanghai Biotecan Pharmaceuticals by Business, 2014-2017

Gross Margin of Shanghai Biotecan Pharmaceuticals, 2013-2017

Shanghai Biotecan Pharmaceuticals' Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2017

Subsidiaries of Jiangsu Superbio Life Science as of Apr 2019

Revenue and Net Income of Jiangsu Superbio Life Science, 2014-2017s

Revenue Breakdown of Jiangsu Superbio Life Science by Business, 2014-2017

Gross Margin of Jiangsu Superbio Life Science, 2014-2017

Revenue and Net Income of Amoy Diagnostics, 2014-2018

Operating Revenue Breakdown of Amoy Diagnostics by Business, 2014-2018

Gross Margin of Amoy Diagnostics, 2014-2018

Gross Margin of Amoy Diagnostics by Business, 2014-2018

Clinical Laboratory Testing Service Process of Amoy Diagnostics

Main Bioassay Service Partners of Amoy Diagnostics

Amoy Diagnostics' Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2018

Revenue and Net Income of Guangdong Hybribio Biotech, 2014-2018

Operating Revenue Breakdown of Guangdong Hybribio Biotech by Product, 2014-2018

Gross Margin of Guangdong Hybribio Biotech by Business, 2014-2018

Guangdong Hybribio Biotech's R&D Costs and % of Total Revenue, 2017-2018

Progress of Committed Fundraising Projects of Guangdong Hybribio Biotech by the end of 2018

Guangdong Hybribio Biotech's Revenue from Independent Clinical Laboratory and % of Total Revenue, 2014-2018

Milestones of Kindstar Global

Some Strategic Partners of ADINOVO